Nanosphere Bullish Stance Maintained at Roth Capital Following An Agreement With HealthTrust
Roth Capital analyst Chris Lewis today maintained a Buy rating on Nanosphere, Inc. (NSPH), with a price target of $3.00 following today’s news that Nanosphere entered into a non-exclusive license-to-hunt supply agreement with the HealthTrust Purchasing Group that will offer HealthTrust members access to Nanosphere’s portfolio of Verigene molecular diagnostics tests.
The analyst stated, “HealthTrust Purchasing Group is one of the largest healthcare supply contracting companies in the US, comprised of 1,400 acute-care facilities. While this agreement is not exclusive and does not guarantee any new business for NSPH, a license-to-hunt agreement with HealthTrust should provide a reasonable tailwind of new sales leads and potential new customer conversions over the coming years, in our opinion. Given NSPH has already been selling into HealthTrust hospitals, we expect this agreement will create a more efficient sales process through standardized GPO pricing and contract terms in place”.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Chris Lewis currently has a one-year average return of 1% and a 50% success rate. Lewis has a 42.6% average loss recommending NSPH, and he is ranked #2205 out of 3123 analysts.